University of Cambridge > > SciSoc – Cambridge University Scientific Society > Prostacyclin and nitric oxide in vascular biology

Prostacyclin and nitric oxide in vascular biology

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Adam.

Sir Salvador Moncada has made monumental contributions to pharmacology and medicine. He determined the mechanism of action of aspirin-like drugs and led the discovery of the enzyme thromboxane synthase and the vasodilator prostacyclin, thus laying the foundation for use of aspirin to prevent heart attack and stroke. He identified nitric oxide as a biological mediator and established its significance in the cardiovascular system and nervous system. As Director of Research at the Wellcome Research Laboratories, he oversaw the discovery and development of many drugs now widely used, including lamotrigine (an anti-epileptic), atovaquone (an anti-malarial) and zomig (for migraine headaches), and initiated the work that resulted in the development of lapatinib for the treatment of breast cancer. Currently the Director of the Institute of Cancer Sciences at the University of Manchester and previously the Director of the UCL Wolfson Institute, Sir Salvador was elected Fellow of the Royal Society in 1988. In another chapter of an extraordinary career, he will discuss his most recent work in cell metabolism, which has led to the finding of the molecular mechanism that coordinates cell proliferation with the provision of metabolic substrates required for this process.

Everyone is welcome. Free for members, £2 on the door for non-members. Followed by refreshments (that means smoothies, cheese and grapes!).

This talk is part of the SciSoc – Cambridge University Scientific Society series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity